Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

ABSTRACT: This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).

DISEASE(S): Neuroendocrine Tumors,Sarcoma,Anaplastic Thyroid Cancer,Thyroid Carcinoma, Anaplastic,Small Cell Lung Cancer,Colorectal Cancer,Small Cell Lung Carcinoma,Small Cell Lung Cancer Metastatic,Soft Tissue Sarcoma,Neoplasms,Metastatic Solid Tumor,Gastric Cancer,Neuroendocrine Tumour,Tumores Sólidos Avanzados

PROVIDER: 2353932 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR